AstronauTx

📰 AstronauTx has been featured in the latest edition of Citeline’s Scrip Asks, where industry leaders share their predictions for biopharma in 2026. In this piece, our CEO Jane Rhodes spoke with Eleanor Malone about the rapidly growing field of neuroscience noting: “Innovation in neuroscience continues to drive real progress and investment, and 2026 will accelerate the focus from late‑stage disease treatment to early‑stage disease prevention.” Jane also emphasised the growing evidence that sleep is a modifiable indicator of neurological decline and highlights biomarkers such as pTau217, which now enable much earlier and more reliable identification and stratification of patients at risk of progressing to chronic neurological disease. 🔗 Read the full article here: https://lnkd.in/eFg9pNAD #ScripAsks2026 #Neuroscience #Neurology #Biotech #Innovation

📰 AstronauTx has been featured in Drug Discovery World as part of its #JPM2026 round-up!   Our CEO, Jane Rhodes, spoke with #DDW about her experience at JPM, commenting: "This JPM was energised, infused with a sense of optimism because biotech feels buoyant again.”   🔗 Read the full article here: https://lnkd.in/eNTN5-pw   #AstronauTx #Neurology #SleepArchitecture #lifesciences  

📢AstronauTx announces the appointment of Adam Croucher as our new Finance Director! Adam brings extensive financial leadership experience from roles across international biotech and pharmaceutical companies, alongside a strong scientific grounding through his PhD in Molecular Biology. This background enables him to combine financial and scientific expertise to support AstronauTx’s mission, and he is passionate about applying these skills to accelerate the development of transformative treatments. His leadership will support #AstronauTx as we advance the development of novel therapeutics to treat Alzheimer's Disease and other neurological disorders by improving sleep architecture. Learn more about Adam's background and career journey below. #neuroscience #neurological #lifesciences #appointment 

Kicking off 2026! 📢 AstronauTx has been named in the ‘Ones to Watch’ feature of the 2026 Sunday Times 100 Tech, recognising the 100 fastest growing tech companies in the UK. The profile also spotlights our co-founder Ruth McKernan, whose track record of turning breakthrough neuroscience into high-impact companies has helped shape some of the most exciting science-led ventures in the UK – and we’re proud to be one of them. 2025 was a year of meaningful progress and recognition for #AstronauTx. Our mission to use pioneering science to improve sleep architecture and develop new treatments for Alzheimer’s and other neurological diseases has gained significant momentum. We welcome the Sunday Times’ recognition of the innovative spirit and unwavering commitment of our team as we work to deliver novel therapies for neurological disease. You can view the full Ones to Watch table featured in the Sunday Times 100 Tech list via this link: https://lnkd.in/eUrnUaVa #sundaytimes100 #OnesToWatch #neurologicaldisease #SundayTimes

📰AstronauTx has been featured in PharmaVoice as part of its first installment of the 'Crystal Ball' series, examining Pharma's year ahead. This piece discusses the regulatory and investment market landscape and how industry leaders believe it will change in 2026. Our CEO Jane Rhodes, spoke with Meagan Parrish about her views on biotech talent moving away from the US. Jane noted: "Substantial changes in scientific policy and funding, economic uncertainty, and shifting immigration policy, combined with a heavily restructured early-stage biotech landscape will prompt expats to reconsider their long-term plans." 🔗 Read further insights from Jane in the full article: https://lnkd.in/gAyq_fRG   #AstronauTx #Neuroscience #NeurologicalDisease #Biotech #SlowWaveSleep

AstronauTx is pleased to announce the appointment of Adam Rosenberg as Chair of the Board. Adam is an accomplished biotech executive with more than two decades of experience in company building across the life sciences industry. He brings extensive operational, strategic and transactional expertise, and deep experience in developing therapeutics in central nervous system disorders. His appointment comes at a pivotal time as AstronauTx advances its innovative pipeline targeting improvements in sleep architecture as a novel approach to treating Alzheimer's disease and other neurodegenerative disorders. Read the full press release here: https://lnkd.in/eWPJzatJ #Neuroscience #Neurodegeneration #Biotech #Appointment #SlowWaveSleep

AstronauTx is pleased to share that it is an industry partner in a major new Medical Research Council (MRC) funded study led by Professor Liz Coulthard at the University of Bristol, investigating whether enhancing slow wave sleep can modify the underlying progression of Alzheimer’s disease. Sleep quality is fundamentally important and sleep dysregulation underpins chronic disease, particularly neurodegenerative conditions like Alzheimer’s disease. Slow wave sleep is the most restorative portion of sleep architecture and drives memory consolidation which is disrupted in early Alzheimer’s disease. This will be the first long-term interventional study to test how improving slow wave sleep influences Alzheimer’s-related changes in people at the early stages of disease. Using home-based sleep monitoring, EEG, blood and CSF biomarkers, and cognitive testing, the trial will generate the most detailed picture to date of how sleep biology shapes Alzheimer’s pathology. For #AstronauTx, this collaboration is strategically important. Our mission is to recapitulate the sleep architecture of a healthy young adult to improve sleep quality, enhance cognitive performance in people in the early stages of Alzheimer’s and potentially slow cognitive decline. The findings from this study will directly inform our pipeline of small molecule therapeutics, with clinical testing of our lead compound planned for early 2027. We’re proud to support research that could open an entirely new therapeutic approach to Alzheimer’s disease. Read more on the MRC website: https://lnkd.in/eszpev-Z #Neuroscience #Alzheimers #Neurodegeneration

📍AstronauTx will be in San Francisco for #JPMHealthcareConference 2026!   Our CEO, Jane Rhodes is looking forward to connecting with industry leaders and innovators. JPM is a prestigious event that brings together top leaders from the global life sciences and investment sectors, and we can't wait to be part of the conversation.   At #AstronauTx we are developing small molecule therapeutics that target brain activity during sleep to treat chronic neurodegenerative diseases.   📩 Reach out to connect with Jane to learn more about the advances AstronauTx has made in selectively targeting sleep quality.   #AstronauTx #Neuroscience #Neurodegeneration #JPM2026 #JPMWeek

📰 AstronauTx has been featured in Drug Discovery World as part of its #LondonLifeSciencesWeek2025 wrap-up!   Our CEO, Jane Rhodes, spoke with #DDW about the themes shaping conversations during #LLSW25, including increased stakeholder involvement and why this year's conference felt like a turning point for the sector. During the week, Jane participated in a panel with Lord Patrick Vallance “on how to attract biotech talent back to the UK, to build on UK talent and strengthen the sector” and noted: "There’s a clear recognition that greater capital infusion is needed to support growth of the biotech industry in the UK.”   🔗 Read more insights from Jane in the full article: https://lnkd.in/e24FNgC6   #AstronauTx #Neuroscience #Neurodegeneration #BrainHealth

AstronauTx will be in San Diego next week for CTAD Clinical Trials on Alzheimer's Disease 2025, 1-4 December 2025.   The 18th Annual #CTAD Conference is an international forum bringing together researchers, academics and industry professionals, all focused on accelerating the development of effective treatments for Alzheimer’s and other neurodegenerative diseases.   Reach out to Bahareh Eftekharzadeh, Head of Discovery Biology and Antonella Pirone, Head of Translation to learn more about how #AstronauTx is developing novel treatments for #Alzheimer’s by targeting the restorative power of slow wave sleep. 💤   #CTAD2025 #Neuroscience #Alzheimers #Neurodegeneration #BrainHealth